"The U.S. Food and Drug Administration today approved Vimizim (elosulfase alfa), the first FDA-approved treatment for Mucopolysaccharidosis Type IVA (Morquio A syndrome). Morquio A syndrome is a rare, autosomal recessive lysosomal storage disease "...
- Patient Information:
Details with Side Effects
Brevital Sodium can be used in adults as follows:
- For intravenous induction of anesthesia prior to the use of other general anesthetic agents.
- For intravenous induction of anesthesia and as an adjunct to subpotent inhalational anesthetic agents (such as nitrous oxide in oxygen) for short surgical procedures; Brevital Sodium may be given by infusion or intermittent injection.
- For use along with other parenteral agents, usually narcotic analgesics, to supplement subpotent inhalational anesthetic agents (such as nitrous oxide in oxygen) for longer surgical procedures.
- As intravenous anesthesia for short surgical, diagnostic, or therapeutic procedures associated with minimal painful stimuli (see WARNINGS).
- As an agent for inducing a hypnotic state.
Brevital Sodium can be used in pediatric patients older than 1 month as follows:
- For rectal or intramuscular induction of anesthesia prior to the use of other general anesthetic agents.
- For rectal or intramuscular induction of anesthesia and as an adjunct to subpotent inhalational anesthetic agents for short surgical procedures.
- As rectal or intramuscular anesthesia for short surgical, diagnostic, or therapeutic procedures associated with minimal painful stimuli.
DOSAGE AND ADMINISTRATION
Facilities for assisting ventilation and administering oxygen are necessary adjuncts for all routes of administration of anesthesia. Since cardiorespiratory arrest may occur, patients should be observed carefully during and after use of Brevital Sodium. Age- and size-appropriate resuscitative equipment (ie, intubation and cardioversion equipment, oxygen, suction, and a secure intravenous line) and personnel qualified in its use must be immediately available.
Preanesthetic medication is generally advisable. Brevital Sodium may be used with any of the recognized preanesthetic medications.
Preparation of Solution
FOLLOW DILUTION INSTRUCTIONS EXACTLY.
Solutions of Brevital Sodium should be freshly prepared and used promptly. Reconstituted solutions of Brevital Sodium are chemically stable at room temperature for 24 hours.
ONLY USE BACTERIOSTATIC-FREE DILUENT – Recommended diluents are based on route of administration (see dilution instructions).
Incompatible diluents: Lactated Ringer's Injection
1% solutions (10 mg/mL) should be prepared for intermittent intravenous and rectal administration; 0.2% solutions (2 mg/mL) should be prepared for continuous intravenous drug administration; 5% solutions (50 mg/mL) should be prepared for intramuscular administration.
Contents of vials should be diluted as follows:
For Intermittent Intravenous And Rectal Administration
The preferred diluent for intermittent intravenous and rectal administration is Sterile Water for Injection. 5% Dextrose Injection, or 0.9% Sodium Chloride Injection are also acceptable diluents.
|Strength||Amount of Diluent to Be Added to the Contents of the Brevital Vial||For 1% methohexital solution (10 mg/mL)|
|200 mg||20 mL||no further dilution needed|
|500 mg||50 mL||no further dilution needed|
|2.5 g||15 mL||add to 235 mL diluent for 250 mL total volume|
When the first dilution is made with the 2.5 g, the solution in the vial will be yellow. When further diluted to make a 1% solution, it must be clear and colorless or should not be used.
For Continuous Intravenous Administration
For continuous drip anesthesia, prepare a 0.2% solution by adding 500 mg of Brevital Sodium to 250 mL of diluent. For this dilution, either 5% glucose solution or isotonic (0.9%) sodium chloride solution ONLY is recommended as the diluent instead of sterile water for injection in order to avoid extreme hypotonicity.
|Strength||Amount of Diluent to Be Added to the Contents of the Brevital Vial||For 0.2% methohexital solution (2 mg/mL)|
|500 mg||15 mL||add to 235 mL diluent for 250 mL total volume|
For Intramuscular Administration
The preferred diluent for intramuscular administration is Sterile Water for Injection. 0.9% Sodium Chloride Injection is also an acceptable diluent.
|Strength||Amount of Diluent to Be Added to the Contents of the Brevital Vial||For 5% methohexital solution (50 mg/mL)|
|200 mg||4 mL||no further dilution needed|
|500 mg||10 mL||no further dilution needed|
|2.5 g||50 mL||no further dilution needed|
Dosage is highly individualized; the drug should be administered only by those completely familiar with its quantitative differences from other barbiturate anesthetics.
Brevital Sodium is administered intravenously in a concentration of no higher than 1%. Higher concentrations markedly increase the incidence of muscular movements and irregularities in respiration and blood pressure.
Induction of anesthesia
For induction of anesthesia, a 1% solution is administered at a rate of about 1 mL/5 seconds. Gaseous anesthetics and/or skeletal muscle relaxants may be administered concomitantly. The dose required for induction may range from 50 to 120 mg or more but averages about 70 mg. The usual dosage in adults ranges from 1 to 1.5 mg/kg. The induction dose usually provides anesthesia for 5 to 7 minutes.
Maintenance of anesthesia
Maintenance of anesthesia may be accomplished by intermittent injections of the 1% solution or, more easily, by continuous intravenous drip of a 0.2% solution. Intermittent injections of about 20 to 40 mg (2 to 4 mL of a 1% solution) may be given as required, usually every 4 to 7 minutes. For continuous drip, the average rate of administration is about 3 mL of a 0.2% solution/minute (1 drop/second). The rate of flow must be individualized for each patient. For longer surgical procedures, gradual reduction in the rate of administration is recommended (see discussion of prolonged administration in WARNINGS). Other parenteral agents, usually narcotic analgesics, are ordinarily employed along with Brevital Sodium during longer procedures.
Brevital Sodium is administered intramuscularly in a 5% concentration and administered rectally as a 1% solution.
Induction of anesthesia
For the induction of anesthesia by the intramuscular route of administration, the usual dose ranges from 6.6 to 10 mg/kg of the 5% concentration. For rectal administration, the usual dose for induction is 25 mg/kg using the 1% solution.
Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration, whenever solution and container permit.
Solutions of Brevital Sodium should not be mixed in the same syringe or administered simultaneously during intravenous infusion through the same needle with acid solutions, such as atropine sulfate, metocurine iodide, and succinylcholine chloride. Alteration of pH may cause free barbituric acid to be precipitated. Solubility of the soluble sodium salts of barbiturates, including Brevital Sodium, is maintained only at a relatively high (basic) pH.
Because of numerous requests from anesthesiologists for information regarding the chemical compatibility of these mixtures, the following chart contains information obtained from compatibility studies in which a 1% solution of Brevital Sodium was mixed with therapeutic amounts of agents whose solutions have a low (acid) pH.
|Active Ingredient||Potency per mL||Volume Used||Immediate||15 min||Physical Change 30 min||1 h|
|Brevital Sodium||10 mg||10 mL||CONTROL|
|Atropine Sulfate||1/150 gr||1 mL||None||Haze|
|Atropine Sulfate||1/100 gr||1 mL||None||Ppt||Ppt|
|Succinylcholine chloride||0.5 mg||4 mL||None||None||Haze|
|Succinylcholine chloride||1 mg||4 mL||None||None||Haze|
|Metocurine Iodide||0.5 mg||4 mL||None||None||Ppt|
|Metocurine Iodide||1 mg||4 mL||None||None||Ppt|
|Scopolamine hydrobromide||1/120 gr||1 mL||None||None||None||Haze|
|Tubocurarine chloride||3 mg||4 mL||None||Haze|
Store between 20° to 25°C (68° to 77°F). (See USP Controlled Room Temperature.)
Brevital® Sodium Vials*:
The 200 mg vials (with 12 mg of anhydrous sodium carbonate) are available as follows:
NDC 42023-148-10 – Single-Use Vials – Pack of 10
The 500 mg vials (with 30 mg anhydrous sodium carbonate) are available as follows:
NDC 42023-105-01 – Multi-Dose Vial – Pack of 1
NDC 42023-105-10 – Multi-Dose Vials – Pack of 10
The 2.5 g vials (with 150 mg anhydrous sodium carbonate) are available as follows:
NDC 42023-106-01 – Multi-Dose Vial – Pack of 1
*In crystalline form.
Manufactured and Distributed by: JHP Pharmaceuticals, LLC Rochester, MI 48307
Last reviewed on RxList: 2/7/2014
This monograph has been modified to include the generic and brand name in many instances.
Additional Brevital Sodium Information
Report Problems to the Food and Drug Administration
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.
Find out what women really need.